药明康德
603259 · CN
603259 Research Preview
---
| Metric | Value |
|---|---|
| **Price** | CNY 124.66 |
| **Daily move** | −0.27% |
| **Overall score** | 57 / 100 (Hold) |
| **Trend** | Bullish |
| **RSI-14 / RSI-6** | 55.73 / 50.53 |
| **MACD histogram** | −0.59 (bearish cross) |
| **Estimated support** | CNY 116.27 (Bollinger lower) |
| **Estimated resistance** | CNY 131.13 (Bollinger upper) |
| **Position in 30-session range** | 72.82% |
| **Volume vs 20-day avg** | −37.45% |
| **Data confidence** | Medium (no news/sentiment feed) |
---
| Indicator | Reading | Interpretation |
|---|---|---|
| **MA structure** | MA5 125.89 > MA10 125.76 > MA20 123.70 > MA60 110.78 | Bullish alignment intact; price +0.78% above MA20 |
| **RSI-14 / RSI-6** | 55.73 / 50.53 | Neutral-constructive; no overbought/oversold signal |
| **MACD** | Line 3.97, Signal 4.55, Hist −0.59 | Bearish crossover above zero line-momentum slowing, not reversing trend |
| **KDJ** | K 47.32, D 50.20, J 41.57 | Soft/repairing; J < K < D suggests short-term weakness |
| **Bollinger Bands** | Upper 131.13 / Mid 123.70 / Lower 116.27 | Price at 56% of band width; mid-band acting as near-term pivot |
| **ATR-14** | 6.69 (5.37% of price) | Elevated volatility; expect ±CNY 6-7 daily swings |
| **OBV** | 545 M; 20-session slope −10.92% | Distribution pressure visible; volume not confirming recent price strength |
| **CCI-20** | 32.38 | Neutral band; no extreme reading |
Confirmed: Bullish MA alignment, price above all key averages, RSI neutral. Conflicted: MACD bearish cross vs. bullish trend; OBV declining while price holds near highs. Missing: No custom indicators supplied; volume today 37% below average, reducing signal reliability.
---
| Metric | Value | Source | Confidence |
|---|---|---|---|
| **PE** | 18.61× | AkShare THS | Medium |
| **PB** | 4.42× | AkShare THS | Medium |
| **PEG proxy** | 1.03 | StockKit scenario model | Medium |
| **StockKit fair-value range** | Bear CNY 134.33 / Base CNY 184.73 / Bull CNY 232.10 | StockKit DCF scenario model | Medium |
| **Base fair-value gap** | +48.2% upside to base case | StockKit DCF scenario model | Medium |
| **5Y growth forecast** | Bear +10% / Base +18% / Bull +24% | StockKit scenario model | Medium |
| **Revenue (FY 2025E)** | CNY 45.46 B | AkShare THS | Medium |
| **Net income (FY 2025E)** | CNY 19.15 B | AkShare THS | Medium |
| **EPS** | CNY 6.70 | AkShare THS | Medium |
| **Book value / share** | CNY 28.23 | AkShare THS | Medium |
| **Gross margin** | 50.40% | AkShare THS | Medium |
| **Net margin** | 37.56% | AkShare THS | Medium |
Interpretation: At 18.6× trailing earnings and a PEG near 1, the stock appears reasonably valued relative to its growth profile. The StockKit DCF model suggests the current price trades at a meaningful discount to even the bear-case fair value (CNY 134), implying the market may be pricing in regulatory or geopolitical risk not captured in pure financials. Margins remain robust (net margin >37%), supporting earnings quality.
---
| Date | Headline | Relevance |
|---|---|---|
| - | *No headlines available* | - |
Assessment: The configured news source returned no items. This creates a blind spot for event-driven catalysts such as earnings releases, regulatory updates, or contract announcements. Investors should independently monitor: - Quarterly earnings (typically late April for Q1). - U.S.-China biotech policy developments (ongoing sensitivity for CRO sector). - Major client contract disclosures.
*Confidence on catalyst timing: Low.*
---
| Source | Status | Reading | Confidence |
|---|---|---|---|
| NewsAPI headline coverage | No headlines | N/A | Low |
| Social sentiment (Reddit, X, StockTwits, local forums) | Not connected | N/A | Low |
Assessment: Without headline or social-media sentiment data, we cannot gauge retail or institutional positioning shifts. The absence of negative headlines is not confirmation of positive sentiment-treat sentiment as a data gap rather than a neutral signal.
---
| Scenario | Trigger condition | Confirmation | Invalidation |
|---|---|---|---|
| **Base (Consolidation)** | Price oscillates CNY 120-130; MACD histogram stabilises near zero | Closes remain above MA20 (123.70); volume stays subdued | Daily close below CNY 116 or above CNY 135 on strong volume |
| **Upside (Breakout)** | Daily close > CNY 131.13 (Bollinger upper) on volume > 90 M | Follow-through above 30-session high CNY 135.17; OBV slope turns positive | Immediate reversal back below CNY 128 within two sessions |
| **Downside (Correction)** | Daily close < CNY 123.70 (MA20/Bollinger mid) on rising volume | Break of CNY 116.27 support; RSI-14 falls below 40 | Quick reclaim of MA20 with bullish MACD cross |
---
| Risk | Evidence | Trigger | Monitoring action |
|---|---|---|---|
| **Momentum exhaustion** | MACD bearish cross; OBV slope −10.9% | Price fails to hold MA20 on two consecutive closes | Track daily MACD histogram and OBV direction |
| **Elevated volatility** | ATR 5.37% of price | Intraday swings exceed CNY 8-10 | Use ATR-based position sizing; avoid tight stops |
| **News/sentiment blind spot** | No headlines or social data | Unexpected regulatory or geopolitical headline | Set alerts for company name + "FDA", "BIOSECURE", "sanctions" |
| **Valuation disconnect** | Market price 7% below StockKit bear-case fair value | Continued underperformance despite solid fundamentals | Compare quarterly earnings vs. model assumptions |
| **Liquidity variance** | Today's volume −37% vs. 20-day avg | Thin sessions may amplify price moves | Prefer limit orders; avoid market orders in low-volume windows |
---
1. MA20 pivot (CNY 123.70): Monitor daily closes relative to this level-most important short-term signal. 2. MACD histogram: Watch for histogram bars to shrink toward zero or flip positive, signalling momentum repair. 3. OBV slope: A turn from negative to flat/positive would confirm accumulation returning. 4. Volume normalisation: Sessions with volume > 70 M (20-day avg) carry higher signal weight. 5. Bollinger upper (CNY 131.13): A close above on expanding volume would trigger upside scenario. 6. News scan: Manually check for earnings dates, regulatory filings, or U.S. legislative updates (BIOSECURE Act progress). 7. Sector peer action: Compare price action with peers (e.g., 000725 康龙化成, 300759 康泰生物) for sector-wide momentum cues.
---
This research preview is generated by StockKit's automated analysis pipeline using publicly available market data and internally computed scenario models. It is intended for informational purposes only and does not constitute personalised investment advice. Valuation ranges labelled "StockKit scenario model" are algorithmic outputs, not analyst consensus targets. Users should verify all data independently and consult a qualified financial adviser before making investment decisions. Past performance is not indicative of future results.
MA5>MA20金叉，多头排列
MACD死叉，MACD在零轴上方，动能减弱
RSI14=56中性
在通道中部
缩量回调，可能企稳
Research boundary
StockKit organizes market data and model output for research workflows. It does not provide personalized advice or trade instructions. Verify important information with primary sources before any investment decision.